| Patent application number | Description | Published |
|---|
| 20080233571 | Method for identifying compounds which affect synaptogenesis - A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. A method is also provided for identifying a compound which affects the formation of synaptic connections. A method is provided for identifying a compound that modulates immediate early gene expression. A method is further provided for increasing the number of excretory synapses of a neuron, including introducing into the neuron a polynucleotide sequence encoding a Narp operatively linked to a promoter, or a Narp polypeptide, thereby increasing the number of excretory synapses of the neuron. A method is provided for treating a subject with a disorder associated with a decrease in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that augments Narp function or expression. A method is provided for treating a subject with a disorder associated with an increase in a function or expression of Narp, including administering to the subject a therapeutically effective of a compound that inhibits Narp function or expression. A method is provided for treating a patient having or at risk of having a disorder associated with decreased Narp expression. The method includes introducing into a cell of a patient having a disorder associated with decreased Narp expression or function a polynucleotide sequence encoding a Narp polypeptide operatively linked to a promoter. A method is provided for treating a subject having a deficiency in a neuron's immediate early gene responsiveness to a stimulus. The method includes administering a nucleic acid encoding a Narp polypeptide to said subject, wherein the administration results in amelioration of the deficiency. | 09-25-2008 |
| 20090123940 | MOLECULES INVOLVED IN SYNAPTOGENESIS AND USES THEREFOR - The present invention is based on the discovery that neuronal pentraxins play a role in the clustering and internalization of AMPA receptors, synaptogenesis, and metabotropic glutamate receptor-mediated long term depression (LTD) of a synapse. Accordingly, there are provided methods of identifying compounds that that modulate mGluR-mediated AMPA receptor internalization and LTD. Further provided are cleavage products of a member of the neuronal pentraxin family, neuronal pentraxin receptor (NPR). Also provided are isolated peptides comprising the Narp association regions 1 and 2 (NAR1 and NAR2, respectively) and the Narp binding motif (NBM) of AMPA receptors. Finally, there are provided antibodies that block binding of neuronal pentraxins to AMPA receptors, in particular, antibodies that bind NAR1, or NAR2, or NBM. | 05-14-2009 |
| Patent application number | Description | Published |
|---|
| 20120251101 | Apparatus to Control Carrier Spacing in a Multi-Carrier Optical Transmitter - Consistent with the present disclosure, data, in digital form, is received by a transmit node of an optical communication system, and is then provided to a modulator that, in turn, modulates light, received from an optical source at one of a plurality of periodically and preferably minimally spaced wavelengths. The plurality of periodically spaced wavelengths or carriers are grouped together with minimal carrier spacing, to form a superchannel. The carrier spacing between adjacent carriers is determined by detecting a beat frequency of a combined optical signal that includes the outputs of two adjacent optical sources. The beat frequency corresponds to a frequency difference between the outputs of the adjacent carriers. This frequency difference should correspond to a desired carrier spacing between each of the plurality of carriers. A frequency error between the beat frequency and the desired carrier spacing is then measured by down-converting the beat frequency with respect to a target reference frequency corresponding to the desired carrier frequency spacing. Based on the determined frequency error, the optical sources are controlled to adjust in frequency to minimize or reduce the frequency error to zero. For every pair of adjacent carriers, the corresponding outputs of the optical sources are compared in the above manner to determine a plurality of frequency errors. Each optical source can thus be tuned in order to realize a precise carrier spacing between each of the adjacent carriers. | 10-04-2012 |
| 20130011140 | SUPPRESSION OF NON-LINEAR EFFECTS IN LOW DISPERSION OPTICAL FIBERS - Consistent with the present disclosure, chromatic dispersion is introduced into an optical communication path including multiple segments or spans of dispersion shifted fiber (DSF). The chromatic dispersion generates phase mismatching between optical signals propagating along the optical communication path, i.e., the optical signals are decorrelated, such that mixing products are reduced inmagnitude, and the noise attributable to four wave mixing is correspondingly reduced. | 01-10-2013 |
| 20140093240 | NONLINEAR COMPENSATION IN WDM SYSTEMS - A compensator device may include a selection switch to receive a first optical signal and provide first and second groups of channels associated with the first optical signal; a polarization beam splitter to receive the first channels, and provide first and second components; a photodiode that provides an electrical signal indicative of an intensity of the first group of channels; a first modulator to receive the electrical signal and the first components and to modulate the first components to form first modulated channels; a second modulator to receive the electrical signal and the second components to modulate the second components to form second modulated channels; a polarization beam combiner to receive the first and second modulated channels to form combined modulated channels; and a coupler to receive the combined modulated channels and the second group of channels to form a second optical signal. | 04-03-2014 |
| Patent application number | Description | Published |
|---|
| 20090093566 | Dental releasing materials - Combining nanosized particles of a source of desired dental restorative, repair or therapeutic materials with strengthening agents in various generally nanosized form such as whiskers, fibers, particles and the like in a resin matrix provides a highly strain resistant composite which more effectively releases the therapeutic agents. The utilization of nano sized particles of the therapeutic agent in the combination enables observation of significantly improved therapeutic results. | 04-09-2009 |
| 20100247605 | Three Dimensional Cell Protector/Pore Architecture Formation for Bone and Tissue Constructs - Living cellular material is encapsulated or placed in a protective material (cell protector) which is biocompatible, biodegradable and has a three-dimensional form. The three dimensional form is incorporated into a matrix that maybe implanted in vivo, ultimately degrade and thereby by replaced by living cell generated material. | 09-30-2010 |
| 20130039990 | INJECTABLE, LOAD-BEARING CELL/MICROBEAD/CALCIUM PHOSPHATE BONE PASTE FOR BONE TISSUE ENGINEERING - The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same. | 02-14-2013 |
| 20130108708 | DENTAL COMPOSITES COMPRISING NANOPARTICLES OF AMORPHOUS CALCIUM PHOSPHATE | 05-02-2013 |
| 20140294985 | BONE PASTES COMPRISING BIOFUNCTIONALIZED CALCIUM PHOSPHATE CEMENTS WITH ENHANCED CELL FUNCTIONS FOR BONE REPAIR - The invention provides injectable, biofunctional agent-containing calcium phosphate cement bone pastes for bone tissue engineering, and methods of making and using the same. | 10-02-2014 |
| 20150299345 | ANTIBACTERIAL MONOMERS, ANTIBACTERIAL RESINS AND DENTAL COMPOSITES COMPRISING THE ANTIBACTERIAL RESINS - Provided herein are antibacterial monomers, antibacterial resins comprising a resin and the monomers, and dental composites comprising the antibacterial resins and a filler, and methods of making the same. The dental composite can optionally contain amorphous calcium phosphate nanoparticles. The dental composites display strongly antibacterial properties, increased calcium and phosphate ion release, and improved mechanical properties. | 10-22-2015 |
| 20160058675 | NANOSTRUCTURED ANTIBACTERIAL AND REMINERALIZING DENTAL BONDING AGENTS AND DENTAL BONDING SYSTEMS - The present invention provides dental bonding agents and dental bonding systems comprising the dental bonding agents. The dental bonding agents of the invention are characterized by having antibacterial properties, and in some aspects of the invention, remineralizing properties. | 03-03-2016 |
| Patent application number | Description | Published |
|---|
| 20130123330 | Dual Targeted siRNA Therapeutics for Treatment of Diabetic Retinopathy and Other Ocular Neovascularization Diseases - The present invention relates to compositions and methods for treating diabetic retinopathy and other ocular neovascularization diseases. In one embodiment, the composition comprises at least two different siRNA duplexes and a pharmaceutically acceptable carrier. One of the duplexes binds to an mRNA molecule that encodes VEGF, and the other binds to an mRNA molecule that encodes VEGFR2. In another embodiment, the composition further comprises an siRNA duplex that binds to an mRNA molecule that encodes TGFβ1. | 05-16-2013 |
| 20130225655 | Combinations of TGFBeta and COX-2 Inhibitors and Methods for Their Therapeutic Application - The present invention provides compositions and methods for using combinations of TGFβ1 and Cox-2 inhibitors and TGFβ1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGFβ1 and Cox-2 at the same time, resulting in significant less scar formation. | 08-29-2013 |
| 20130345284 | siRNA Compositions and Methods for Treatment of HPV and Other Infections - The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections. | 12-26-2013 |
| 20160068843 | Compositions and Methods for "Resistance-Proof" SiRNA Therapeutics for Influenza - The present invention relates to compositions and methods for development of resistance-proof siRNA therapeutics for prevention and treatment of influenza viral infections. The compositions include a pharmaceutical composition comprising siRNA molecules that target conserved regions of an influenza virus gene and a pharmaceutically acceptable polymeric carrier. In one embodiment, the polymeric carrier condenses the molecules to form a nanoparticle. | 03-10-2016 |
| Patent application number | Description | Published |
|---|
| 20120020956 | ACTIVATION OF SODIUM POTASSIUM ATPASE - Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase. | 01-26-2012 |
| 20130310542 | Inotropic Effects of Antibodies on Cardiac Contraction - The present invention shows that site-specific antibodies to the (Na | 11-21-2013 |
| 20130344566 | Inotropic Antibodies And Therapeutic Uses Thereof - Antibodies binding to sites on the alpha-subunit of the (Na | 12-26-2013 |
| 20130345407 | Activation of Sodium Potassium ATPase - Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase. | 12-26-2013 |
| 20140221609 | Activation of Sodium Potassium ATPase - Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase. | 08-07-2014 |
| 20150175709 | Inotropic Antibodies And Therapeutic Uses Thereof - Antibodies binding to sites on the alpha-subunit of the (Na | 06-25-2015 |
| 20150259438 | METHODS OF INHIBITING PLATELET AGGREGATION AND PREVENTING THROMBOSIS USING ANTIBODIES THAT BIND (NA+ + K+)-ATPASE BETA SUBUNIT - Methods of inhibiting platelet aggregation using antibodies having binding specificity for the β subunit of the (Na | 09-17-2015 |
| 20150291700 | Sodium Pump Antibody Agonists And Methods Of Treating Heart Disease Using The Same - Antibodies that are agonists of sodium pump (Na | 10-15-2015 |
| 20160083463 | Sodium Pump Antibody Agonists And Methods Of Treating Heart Disease Using The Same - Antibodies that are agonists of sodium pump (Na | 03-24-2016 |
| Patent application number | Description | Published |
|---|
| 20110189548 | IONIC ADDITIVES FOR ELECTROCHEMICAL DEVICES USING INTERCALATION ELECTRODES - An electrochemical cell comprising a cathode comprising an electrode active material that reversibly intercalates and de-intercalates any of cations and molecules; an anode comprising an electrode active material that reversibly intercalates and de-intercalates any of cations, anions, and molecules; a separator material that separates the cathode from the anode; and an electrolyte comprising a base electrolyte composition, an ionic compound additive, and a solvent comprising any of aqueous and non-aqueous electrolyte solvents, wherein the additive dissolves in the base electrolyte composition as well a majority of the aqueous or non-aqueous electrolyte solvents, wherein the additive comprises a solubility of at least approximately 0.01 in the base electrolyte composition, wherein the additive dissociates into corresponding cations and anions upon dissolution, and wherein the cations originate from a metal element and reduce to an elemental form at a potential that is at least approximately 0.50 V above that of lithium. | 08-04-2011 |
| 20110281177 | NONAQUEOUS ELECTROLYTE SOLVENTS AND ADDITIVES - A series of polar and aprotic organic molecules, which, when used as solvents or additives in nonaqueous electrolytes, afford improved performance for electrochemical cells that operate at high voltages. These polar and aprotic solvents or additives may contain at least one unsaturated functionality per molecule. The unsaturated functionality is conjugated with the polar functionality of the molecule. The unsaturated functionality that is either a double or triple bond could be between carbon-carbon, or between carbon-heteroatom, or between hetroatom-heteroatom. Nonaqueous electrolyte solutions are provided comprising one or more lithium salts dissolved in the mixture solvents, which comprises, in all possible ratios, at least one of the polar, aprotic and unsaturated solvent or additives, one or more cyclic carbonic diesters such as ethylene carbonate, and one or more acyclic carbonic diesters such as dimethyl carbonate, diethyl carbonate, and ethylmethyl carbonate. | 11-17-2011 |
| 20120225359 | Electrolytes in Support of 5 V Li ion Chemistry - This invention described the preparation of a series of compounds selected from the group comprising tris(1,1,1,3,3,3-hexafluoro-iso-propyl)phosphate, tris(perfluoroethyl)phosphate, tris(perfluoro-iso-propyl)phosphate, bis(1,1,1-trifluoroethyl)fluorophosphate, tris(1,1,1-trifluoroethyl)phosphate, hexakis(1,1,1-trifluoroethoxy)phosphazene, tris(1,1,1-trifluoroethoxy)trifluorophosphazene, hexakis(perfluoro-t-butyl)phosphazene and tris(perfluoro-t-butyl)phosphate. These compounds may be used as co-solvents, solutes or additives in non-aqueous electrolytes in various electrochemical devices. The inclusion of these compounds in electrolyte systems can enable rechargeable chemistries at high voltages that are otherwise impossible with state-of-the-art electrolyte technologies. These compounds are chosen because of their beneficial effect on the interphasial chemistries formed at high potentials, such as 5.0 V class cathodes for new Li ion chemistries. These compounds may be used in Li ion battery technology and in any electrochemical device that employs non-aqueous electrolytes for the benefit of high energy density resultant from high operating voltages. | 09-06-2012 |
| 20120276445 | PURE FORMS OF LITHIUM BORATE SALTS AND THE PROCESS PRODUCING SUCH FORMS - An electrolytic solution comprising a purified lithium borate salt that when used in lithium ion battery, delivers superior performances that include negligible irreversible capacity upon cell formation, low impedance on both cathode and anode, and excellent stability when operated at high temperatures. | 11-01-2012 |
| 20150079483 | OXIRANE-BASED ADDITIVES IN SUPPORT OF FIVE VOLT LITHIUM ION CHEMISTRY - The present disclosure relates to several families of commercially available oxirane compounds that can be used as electrolyte co-solvents, solutes, or additives in non-aqueous electrolyte and their test results in various electrochemical devices. The presence of these compounds can enable rechargeable chemistries at high voltages. These compounds were chosen for their beneficial effect on the interphasial chemistries that occur at high potentials on the classes of 5.0V cathodes used in experimental Li-ion systems. | 03-19-2015 |
| 20150079484 | ELECTROLYTE ADDITIVES IN SUPPORT OF FIVE VOLT LITHIUM ION CHEMISTRY - The present disclosure relates to additives for electrolytes and preparation of aluminum-based, silicon-based, and bismuth-based additive compounds that can be used as additives or solutes in electrolytes and test results in various electrochemical devices. The inclusion of these aluminum, silicon, and bismuth compounds in electrolyte systems can enable rechargeable chemistries at high voltages that are otherwise unsuitable with current electrolyte technologies. These compounds are so chosen because of their beneficial effect on the interphasial chemistries formed at high potentials, such as 5.0 V class cathodes for Li-ion chemistries. The application of these compounds goes beyond Li-ion battery technology and covers any electrochemical device that employs electrolytes for the benefit of high energy density resultant from high operating voltages. | 03-19-2015 |
| Patent application number | Description | Published |
|---|
| 20130296933 | Drug Loaded Microfiber Sutures for Ophthalmic Application - Ophthalmic suture materials made from biocompatible and biodegradable polymers with high tensile strength for use in drug delivery, methods of making them, and method of using them for ocular surgery and repair have been developed. The suture materials are made from a combination of a biodegradable, biocompatible polymer and a hydrophilic biocompatible polymer. In a preferred embodiment the suture materials are made from a poly(hydroxyl acid) such as poly(l-lactic acid) and a polyalkylene oxide such as poly(ethylene glycol) or a polyalkylene oxide block copolymer. The sutures entrap (e.g., encapsulate) one or more therapeutic, prophylactic or diagnostic agents and provide prolonged release over a period of at least a week, preferably a month. | 11-07-2013 |
| 20140329913 | NANOPARTICLES WITH ENHANCED MUCOSAL PENETRATION OR DECREASED INFLAMMATION - Nanoparticles formed by emulsion of one or more core polymers, one or more surface altering materials, and one or more low molecular weight emulsifiers have been developed. The particles are made by dissolving the one or more core polymers in an organic solvent, adding the solution of the one or more core polymers to an aqueous solution or suspension of the emulsifier to form an emulsion, and then adding the emulsion to a second solution or suspension of the emulsifier to effect formation of the nanoparticles. In the preferred embodiment, the molecular weight of the emulsifiers is less than 1500, 1300, 1200, 1000, 800, 600, or 500 amu. Preferred emulsifiers include cholic acid sodium salt, dioctyl sulfosuccinate sodium, hexadecyltrimethyl ammonium bromide, saponin, TWEEN® 20, TWEEN® 80, and sugar esters. The surface altering materials are present in an amount effective to make the surface charge of the particles neutral or essentially neutral when the one or more emulsifiers are charged. The emulsifiers have an emulsification capacity of at least about 50%, preferably at least 55, 60, 65, 70, 75, 80, 85, 90, or 95%. | 11-06-2014 |
| 20150086701 | AERATED OIL CONTAINING SUCROSE FATTY ACID ESTER AND HYDROPHOBIN - The present invention relates to an oil containing gas bubbles, sucrose fatty acid ester and hydrophobin. Moreover the invention relates to a method of making these products, as well as using this composition to reduce spattering during shallow frying of food products. Aerated oil compositions are prepared which are stable during storage and remain homogeneous with respect to the hydrophobin. | 03-26-2015 |
| 20150327565 | METHOD FOR PRODUCTION OF AERATED WATER-IN-OIL EMULSIONS AND AERATED EMULSIONS - The present invention relates to a method for the production of aerated water-in-oil emulsions containing sucrose fatty acid esters. The invention further relates to aerated water-in-oil emulsions containing sucrose fatty acid esters, and to use of the composition for shallow flying and baking of food products. The method comprises a step wherein an oil is mixed with sucrose fatty acid ester, followed by aeration of this mixture. The obtained foamed oil is mixed with a water-in-oil emulsion. | 11-19-2015 |
| Patent application number | Description | Published |
|---|
| 20090028815 | Diazabenzo[De]anthracen-3-one Compounds and Methods for Inhibiting Parp - The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein. | 01-29-2009 |
| 20090088407 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP - The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein. | 04-02-2009 |
| 20090098084 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects. | 04-16-2009 |
| 20090298837 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP - The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein. | 12-03-2009 |
| 20110092478 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP - The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein. | 04-21-2011 |
| 20120115873 | DIAZABENZO[DE] ANTHRACEN-3-ONE COMPOUNDS AND METHODS FOR INHIBITING PARP - The present invention relates to diazabenzo[de]anthracen- | 05-10-2012 |
| 20120309717 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP - The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein. | 12-06-2012 |
| 20130011365 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radio sensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects. | 01-10-2013 |
| 20150141429 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects. | 05-21-2015 |
